
Releases
Enliven Therapeutics Secures $400 Million in Upsized Public Offering
Burlingame-based Enliven Therapeutics has priced an upsized public offering of common stock and pre-funded warrants, aiming to raise approximately $400 million. The clinical-stage biopharmaceutical firm is issuing over 8.9 million shares at $37.50 each to accelerate its development of small molecule precision medicine therapies.
















